Kovitz Investment Group Partners LLC Has $3.54 Million Stake in Boston Scientific Corporation $BSX

Key Points

• Kovitz Investment Group Partners LLC increased its stake in Boston Scientific by 78.1% in Q1, holding over 35,000 shares valued at approximately $3.5 million.
• Several institutional investors have also grown their positions, contributing to a total of 89.07% ownership of the company by institutional investors.
• Analysts have a consensus Buy rating for Boston Scientific, with an average target price of $117.50, reflecting anticipated growth in the company's financial performance.

Kovitz Investment Group Partners LLC raised its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 78.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,066 shares of the medical equipment provider's stock after acquiring an additional 15,375 shares during the period. Kovitz Investment Group Partners LLC's holdings in Boston Scientific were worth $3,537,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of BSX. Brighton Jones LLC lifted its stake in Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock worth $2,445,000 after purchasing an additional 226 shares during the last quarter. Bank Pictet & Cie Europe AG boosted its stake in Boston Scientific by 40.8% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock valued at $6,529,000 after buying an additional 21,173 shares in the last quarter. Highview Capital Management LLC DE grew its position in Boston Scientific by 6.2% in the fourth quarter. Highview Capital Management LLC DE now owns 24,507 shares of the medical equipment provider's stock valued at $2,189,000 after acquiring an additional 1,439 shares during the last quarter. GeoWealth Management LLC grew its holdings in shares of Boston Scientific by 11.1% during the 4th quarter. GeoWealth Management LLC now owns 11,450 shares of the medical equipment provider's stock valued at $1,023,000 after purchasing an additional 1,147 shares during the last quarter. Finally, First Trust Advisors LP lifted its stake in shares of Boston Scientific by 160.9% in the 4th quarter. First Trust Advisors LP now owns 511,920 shares of the medical equipment provider's stock valued at $45,725,000 after acquiring an additional 315,708 shares during the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Stock Performance

Shares of NYSE BSX traded up $0.9720 during trading hours on Friday, reaching $106.1820. The stock had a trading volume of 5,311,038 shares, compared to its average volume of 7,542,365. Boston Scientific Corporation has a twelve month low of $78.53 and a twelve month high of $108.94. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The business's fifty day moving average is $103.97 and its two-hundred day moving average is $102.14. The company has a market cap of $157.34 billion, a price-to-earnings ratio of 63.20, a PEG ratio of 2.55 and a beta of 0.66.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. The company had revenue of $5.06 billion during the quarter, compared to analysts' expectations of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business's revenue was up 22.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, research analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Activity

In related news, Director Edward J. Ludwig sold 4,000 shares of the firm's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the transaction, the director owned 18,479 shares in the company, valued at $1,959,328.37. This trade represents a 17.79% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Yoshiaki Fujimori sold 2,901 shares of the company's stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the completion of the sale, the director owned 2,081 shares in the company, valued at $222,646.19. This trade represents a 58.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 345,029 shares of company stock valued at $35,976,603. 0.50% of the stock is owned by company insiders.

Analyst Ratings Changes

BSX has been the subject of a number of research reports. Barclays raised their price objective on shares of Boston Scientific from $125.00 to $133.00 and gave the company an "overweight" rating in a report on Thursday, July 24th. Citigroup restated a "buy" rating and set a $125.00 target price (up previously from $119.00) on shares of Boston Scientific in a research report on Thursday, May 22nd. Wells Fargo & Company raised their price target on shares of Boston Scientific from $118.00 to $124.00 and gave the stock an "overweight" rating in a report on Thursday, July 24th. Wall Street Zen upgraded Boston Scientific from a "hold" rating to a "buy" rating in a report on Tuesday, April 29th. Finally, Robert W. Baird raised their target price on Boston Scientific from $117.00 to $123.00 and gave the company an "outperform" rating in a report on Thursday, July 24th. Three research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $117.50.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.